MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma

Oncotarget

Volumn 6, Issue 17, 2015, Pages 14993-15007

  Du, Juan ^a   Liu, Shuyan ^a   He, Jie ^a   Liu, Xi ^a   Qu, Ying ^a   Yan, Wenqing ^a   Fan, Jianling ^a   Li, Rong ^a   Xi, Hao ^a   Fu, Weijun ^a   Zhang, Chunyang ^a   Yang, Jing ^b   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

MiRNA 451; Multiple myeloma; PI3K Akt mTOR; Side population; Stemness

Indexed keywords

8-ETHOXY-2-(4-FLUOROPHENYL)-3-NITRO-2H-CHROMENE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BENZOPYRAN DERIVATIVE; BORTEZOMIB; MELPHALAN; MICRORNA; MIRN451 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MULTIPLE MYELOMA; NONOBESE DIABETIC MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SIDE POPULATION CELL; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BENZOPYRANS; BLOTTING, WESTERN; BORTEZOMIB; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELPHALAN; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; OXIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS; TUBEROUS SCLEROSIS;

EID: 84934300731     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3802     Document Type: Article

References (32)

1. Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010;24 Suppl 1:S5-11.
2. Tan D, Chng WJ, Chou T, Nawarawong W, Hwang SY, Chim CS, et al. Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e571-81.
3. Delude C. Tumorigenesis: Testing ground for cancer stem cells. Nature. 2011;480:S43-5.
4. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332-6.
5. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68:190-7.
6. Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, et al. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012;18:6155-68.
7. Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45 low/-CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia. 2012;26:2530-7.
8. Nara M, Teshima K, Watanabe A, Ito M, Iwamoto K, Kitabayashi A, et al. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. PLoS One. 2013;8:e56954.
9. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797-806.
10. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A. 2007;104:4048-53.
11. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008;26:2895-900.
12. Loh YS, Mo S, Brown RD, Yamagishi T, Yang S, Joshua DE, et al. Presence of Hoechst low side populations in multiple myeloma. Leuk Lymphoma. 2008;49:1813-6.
13. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117:4409-19.
14. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-33.
15. Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14:535-48.
16. Bhardwaj A, Arora S, Prajapati VK, Singh S, Singh AP. Cancer "Stemness"-Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential. Curr Drug Targets. 2013;14:1175-84.
17. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11:252-63.
18. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028-34.
19. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood. 2012;119:3571-7.
20. Luo Z, Wen G, Wang G, Pu X, Ye S, Xu Q, et al. MicroRNA-200C and-150 Play an Important Role in Endothelial Cell Differentiation and Vasculogenesis by Targeting Transcription Repressor ZEB1. Stem Cells. 2013;31:1749-62.
21. Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011;29:1661-71.
22. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature. 2009;461:218-23.
23. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet. 2010;11:843-54.
24. Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, et al. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS One. 2012;7:e50005.
25. Li J, Zhu J, Cao B, Mao X. The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma. Curr Pharm Des. 2014;20:125-35.
26. Mao X, Cao B, Wood TE, Hurren R, Tong J, Wang X, et al. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood. 2011;117:1986-97.
27. Kellner J, Liu B, Kang Y, Li Z. Fact or fiction-identifying the elusive multiple myeloma stem cell. J Hematol Oncol. 2013;6:91.
28. Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, et al. RARalpha2 expression confers myeloma stem cell features. Blood. 2013;122:1437-47.
29. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009;15:2281-90.
30. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582-8.
31. Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR Pathway. Am Soc Clin Oncol Educ Book. 2013;2013:395-401.
32. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296-303.